Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of “Buy” from Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has earned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $11.71.

Several analysts recently issued reports on the stock. Oppenheimer assumed coverage on shares of Rani Therapeutics in a research report on Friday, August 2nd. They issued an “outperform” rating and a $17.00 price target for the company. HC Wainwright cut their price objective on shares of Rani Therapeutics from $13.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Maxim Group began coverage on shares of Rani Therapeutics in a report on Friday, June 14th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, Rodman & Renshaw began coverage on shares of Rani Therapeutics in a report on Thursday, June 13th. They set a “buy” rating and a $10.00 price objective on the stock.

Rani Therapeutics Stock Performance

NASDAQ RANI opened at $2.34 on Friday. The company has a fifty day simple moving average of $2.60 and a 200 day simple moving average of $3.92. Rani Therapeutics has a 12-month low of $1.82 and a 12-month high of $8.75. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 3.10. The company has a market cap of $117.98 million, a P/E ratio of -1.81 and a beta of 0.12.

Rani Therapeutics (NASDAQ:RANI) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. Sell-side analysts predict that Rani Therapeutics will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rani Therapeutics

An institutional investor recently raised its position in Rani Therapeutics stock. Vanguard Group Inc. increased its stake in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 2.5% during the first quarter, according to its most recent filing with the SEC. The fund owned 685,303 shares of the company’s stock after buying an additional 16,956 shares during the quarter. Vanguard Group Inc. owned 1.37% of Rani Therapeutics worth $2,131,000 at the end of the most recent quarter. 30.19% of the stock is currently owned by institutional investors and hedge funds.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.